Illumina Gets Order Worth $17M Over Next Five Years
Illumina, Inc. (NASDAQ: ILMN) today announced it was awarded a contract from the U.S. Food and Drug Administration (FDA) to provide the agency with MiSeq sequencing systems and reagents for conducting whole genome analysis on produce and produce-related environmental Salmonella and shigatoxigenic E. coli isolates. The contract is worth up to $17 million over a period of five years.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.